Primary peritoneal papillary serous adenocarcinoma: Clinical and management aspects

Altaras, Marco M.; Aviram, R.; Cohen, Ira A.; Córdoba, María Alejandra; Weiss, Eric G.; Beyth, Y

doi:10.1016/0020-7292(92)90359-q

Cited by 22 publications

(35 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the study population was smaller than other previous studies, the median survival reported in the current study was greater than that reported in previous studies (2,5,6,12,19,21), between 11.3～17.8 months. Additional studies are needed to confirm these findings.…”

Section: Discussioncontrasting

confidence: 54%

“…Skates et al (17) reported a case of a patient that, based on a rising level of CA-125, received surgery and was found to have a peritoneal papillary serous carcinoma. Altaras et al (2) described that CA-125 measurements correlated with the clinical status of disease. Similar to ovarian cancer, patients with PPC have CA-125 values that are useful for diagnosis and follow up of response to therapy.…”

Section: Discussionmentioning

confidence: 99%

“…However, it spares or only minimally involves the ovaries. Histologically, it is indistinguishable from primary epithelial ovarian carcinoma and is diagnosed in the absence of other identifiable primary sites (2). Although the histopathological and clinical features of PPC have been described in several reports, the behavior of this disease entity remains obscure (3～6).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Complications of Acute Pancreatitis Misdiagnosed as Primary Serous Papillary Carcinoma

Lee¹,

Park²

2018

Korean J Pancreas Biliary Tract

View full text Add to dashboard Cite

Purpose: The goal of this study was to determine the clinical and therapeutic characteristics of women with a primary peritoneal carcinoma (PPC). Results:The median overall survival of all patients was 23.1 months. The estimated 3-year survival rate was 29% (SE, 13% ). The response rate to first-line platinum-based chemotherapy was 79% and the median time to treatment failure was 9.9 months (95% confidence interval, 1.38～ 18.4 months). By univariate and multivariate analysis, performance status was the only significant factor associated with overall survival (p＜0.05).Conclusion: W e evaluated the clinical characteristics and treatment response of patients with a primary peritoneal carcinoma. Our results showed that it is possible to achieve long-term survival in patients with PPC. A further clinical study is to need to establish clinical characteristics and treatment outcomes.

show abstract

Section: Discussioncontrasting

confidence: 54%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Complications of Acute Pancreatitis Misdiagnosed as Primary Serous Papillary Carcinoma

Lee¹,

Park²

2018

Korean J Pancreas Biliary Tract

View full text Add to dashboard Cite

show abstract

“…The diagnosis of PPC was confirmed after a review of the operative and pathological findings of each case, and was based on the Gynecologic Oncology Group (GOG) criteria described by Bloss et al(1993): (1) The ovaries are normal in size or enlarged by a benign process; (2) The involvement in the extraovarian sites must be greater than the involvement on the surface of either ovary; (3) Microscopically, the ovaries are not involved with the tumor or exhibited only serosal or cortical implants less than 5 mm×5 mm; (4) The histopathological and cytological characteristics of the tumor are predominantly of the serous type. Since PPC cases with nonserous histology have been reported (Altaras et al, 1990), we included cases with nonserous Mullerian histology that fulfilled other inclusion criteria. Surgical staging was performed according to the Federation International of Gynecology and Obstetrics (FIGO;1985) staging criteria for ovarian cancer.…”

Section: Methodsmentioning

confidence: 99%

Advanced primary peritoneal carcinoma: clinicopathological and prognostic factor analyses

Chao

Cui

et al. 2008

J. Zhejiang Univ. Sci. B

View full text Add to dashboard Cite

Abstract:Objective: To investigate the factors favoring a positive prognosis for advanced primary peritoneal carcinoma (PPC). Methods: Twenty-four cases meeting the criteria for PPC were analyzed retrospectively for the clinicopathologic profiles. Immunohistochemistry was used to determine the expressions of p53, Top2α, Ki-67 and Her-2/neu. Then all these clinicopathological factors and molecular markers were correlated with the prognosis. Results: There were 15 cases of primary peritoneal serous papillary carcinoma (PPSPC), 6 cases of mixed epithelial carcinoma (MEC) and 3 cases of malignant mixed Mullerian tumor (MMMT). All patients underwent cytoreductive surgery with optimal debulking achieved in 3 cases. Among those receiving first-line chemotherapy, 13 patients received the TP regimen (paclitaxel-cisplatin or carboplatin) and 7 patients received the PAC regimen (cisplatin-doxorubicin-cyclophosphamide). The median overall survival of all patients was 42 months, while the breakdown for survival time for patients with PPSPC, MMT and MEC was 44, 13 and 19 months, respectively. The expressions of p53, Top2α and Ki-67 were all demonstrated in 11 cases respectively. None showed the expression of Her-2/neu. There were significant differences in the median survival between patients with PPSPC and those with MMMT (44 months vs 13 months, P<0.05), also between patients receiving TP combination and those receiving the PAC regimen (75 months vs 28 months, P<0.05).Another significant difference in the median progression-free survival (PFS) was identified between patients with positive p53 immunostaining and those with negative p53 immunostaining (15 months vs 47 months, P<0.05), whereas age, menopausal status, residual tumor size and the other molecular factors did not significantly impact survival. Conclusion: Patients with PPC should be treated with a comprehensive management plan including appropriate cytoreductive surgery and responsive chemotherapy. Overestimating an optimal debulking surgery may not benefit survival. The pathologic subtype, chemotherapy regimen and p53 overexpression were significant prognostic factors.

show abstract

“…

Primary papillary serous carcinoma of the peritoneum shares many identical features with its ovarian analogue, serous ovarian papillary carcinoma, and two theories have been proposed to explain their similarities.

…”

mentioning

confidence: 99%

CT appearance of primary papillary serous carcinoma of the peritoneum.

Stafford-Johnson

Bree²,

Francis³

et al. 1998

American Journal of Roentgenology

View full text Add to dashboard Cite

P rimary papillary serous carci noma of the peritoneum is a rare primary tumor of the peritoneum that is found predominantly in elderly, post menopausal women [1 ]. The incidence of primary papillary serous carcinoma of the peritoneum has been estimated to be be tween 6.5% and 7.5% of all casesof initially clinically suspected ovarian epithelial carci noma or papillary serouscarcinoma when re assessed in retrospective series [2].Primary papillary serous carcinoma of the peritoneum shares many identical features with its ovarian analogue, serous ovarian papillary carcinoma, and two theories have been proposed to explain their similarities. The first suggests that primary papillary se rous carcinoma of the peritoneum arises from malignant degeneration of nests of ovarian tis sue remnants that are left within the peri toneum during the process of embryonic gonadal migration [3]. The second theory sug gests that the similarities of the two entities are based on the common origin of ovarian epithelium and pentoneum from mesoderm that has mGllerian potential [4]. Histologi cally, primary papillary serous carcinoma of the peritoneum and serous ovarian papillary carcinomaareindistinguishable, althoughpri mary papillary serous carcinoma of the peritoneum characteristically involves the ovaries only superficially or may totally lack an ovarian component [5].To our knowledge, the radiologic features of primary papillary serous carcinoma of the peritoneum have not been reported. The aim of this study was to describe the CT features of pathologically proven primary papillary serous carcinoma of the peritoneum in seven patients. Materials and Methods PatientsSeven patients with pathologically proven pri mary papillary serous carcinoma of the perito neum who had undergone abdominal and pelvic CT formedthestudypopulation. All patientswere women who were 40â€"77 years old (mean age, 59 years old). Six (86%) of the seven patients were postmenopausal. The presenting complaints were nonspecific and included abdominal pain (n = 5), anorexia (n = 3), and bloating (n = 2). Four pa tients had a combination of symptoms. Two pa tients had peritoneal masses detected unexpectedly while undergoing elective surgery (hysterectomy; opencholecystectomy). Thesetwo patientssubse quently underwent CT. In a third patient who was beingevaluated for abdominal pain,CT revealed a large peritoneal mass that abutted the transverse Received January15,1998; acceptedafterrevision March16,1998. CONCLUSION. The presenceof peritonealmasses, extensiveomentalcalcification,and the absence of an ovarian mass on CTâ€"particularly in postmenopausal womenâ€"is highly suggestive of primary papillary serous carcinoma of the peritoneum and should alert the radi ologist to the possibility of this diagnosis. Downloaded from www.ajronline.org by 54.245.55.244 on 05/11/18 from IP address 54.245.55.244.

show abstract

Primary peritoneal papillary serous adenocarcinoma: Clinical and management aspects

Cited by 22 publications

References 0 publications

Complications of Acute Pancreatitis Misdiagnosed as Primary Serous Papillary Carcinoma

Complications of Acute Pancreatitis Misdiagnosed as Primary Serous Papillary Carcinoma

Advanced primary peritoneal carcinoma: clinicopathological and prognostic factor analyses

CT appearance of primary papillary serous carcinoma of the peritoneum.

Contact Info

Product

Resources

About